ALIVUS · NSE
Alivus Life Sciences Limited
₹1,430.8
+3.10% (+₹43)
Prev. close
₹1,387.8
Volume
3,04,330
Delivery %
64.1%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Alivus Life Sciences Limited
Alivus Life Sciences Limited develops and manufactures active pharmaceutical ingredients in India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. It offers various APIs, such as amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, solifenacin, atovaquone, etoricoxib, dapagliflozin, and sitagliptin for therapeutic areas, including cardiovascular, central nervous system, diabetes, oncology, urology, and pain management, as well as anti-fungal, anti-histaminic, anti-acne, anti-emetics immunomodulators, anti-ulceratives, immunosuppressant, respiratory agent, ophthalmologic agent, anti-spasmodic, and urology. The company also provides contract development and manufacturing comprising process development, analytical development and support, and API and intermediate manufacturing; and research and development, intellectual property, quality and compliance, customer experience, regulatory support. In addition, it exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited operates as a subsidiary of Nirma Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Yasir Yusufali Rawjee Ph.D.
Headquarters
Mumbai
Employees
2,272
Website
alivus.comExchange
View on NSE ↗Key stats
Market cap
₹17,566.14 Cr
P/E ratio (TTM)
29.2
Dividend yield
0.36%
EPS (TTM)
₹48.99
Beta (1Y · daily vs NIFTY 50)
0.58
Beta (5Y · monthly vs NIFTY 50)
0.83
Shares float
3.08 Cr
EPS · quarter ended Jun 2026
₹13.01
Financial Performance
01 · Financials
The first plotted growth figure is computed against Mar 2022 revenue as filed with BSE; the two sources' revenue definitions differ by 5.5% on Mar 2023. FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹2,123.21 Cr | ₹2,047.84 Cr | ₹2,184.77 Cr | ₹2,339.84 Cr | ₹2,504.19 Cr | |
| EBITDA | — | ₹630.76 Cr | ₹671.25 Cr | ₹686.29 Cr | ₹717.15 Cr | ₹832.04 Cr |
| — | ₹418.72 Cr | ₹466.96 Cr | ₹470.89 Cr | ₹485.63 Cr | ₹564.48 Cr | |
| Diluted EPS | — | ₹35.63 | ₹38.11 | ₹38.38 | ₹39.52 | ₹45.9 |
Revenue, Depreciation & amortisation, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,997.08 Cr | ₹2,471.01 Cr | ₹2,702.15 Cr | ₹2,850.41 Cr | ₹3,411.45 Cr | ₹3,982.90 Cr | |
| Total debt | — | ₹2.88 Cr | ₹19.36 Cr | ₹17.15 Cr | ₹56.61 Cr | ₹56.77 Cr |
| Stockholders' equity | ₹752.75 Cr | ₹2,054.31 Cr | ₹2,138.21 Cr | ₹2,332.32 Cr | ₹2,817.37 Cr | ₹3,332.13 Cr |
CWIP, Others, Total debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹597.59 Cr | ₹306.01 Cr | ₹413.52 Cr | ₹391.52 Cr | ₹565.41 Cr | |
| Investing cash flow | — | ₹-122.23 Cr | ₹-146.75 Cr | ₹-116.48 Cr | ₹-615.65 Cr | ₹-570.15 Cr |
| — | ₹-78.80 Cr | ₹-387.59 Cr | ₹-279.44 Cr | ₹-6.23 Cr | ₹-64.34 Cr | |
| Capital expenditure | — | ₹-132.17 Cr | ₹-162.80 Cr | ₹-128.97 Cr | ₹-166.19 Cr | ₹-307.06 Cr |
| End cash position | ₹115.60 Cr | ₹512.16 Cr | ₹283.82 Cr | ₹301.41 Cr | ₹71.06 Cr | ₹1.98 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Aug 21–Sep 21(2Q) | Dec 21–Jun 24(11Q) | Sep 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25–Dec 25(2Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|
| Promoter | 82.84% | 82.85% | 75.00% | 74.99% | 74.94% | 74.91% | 74.87% |
| Public | 17.16% | 17.15% | 25.00% | 25.01% | 25.06% | 25.09% | 25.13% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Alivus Life Sciences Limited | ₹17,050.50 Cr | ₹1,386.8 | 28.3 | 5.12 | 16.9% | 0.02 | +7.0% | +49.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Why You Might Be Interested In Alivus Life Sciences Limited (NSE:ALIVUS) For Its Upcoming Dividend
Alivus Life Sciences Limited is set to go ex-dividend in three days, with an upcoming dividend of ₹5.00 per share. The company's dividend is well-covered by both profits and free cash flow, with payout ratios of 11% and 24% respectively. While earnings per share have grown 8.5% annually over five years, dividend payments per share have declined by 25% annually in the same period.
Alivus Life Sciences Acquires 76% Stake in IQGenX Pharma
Alivus Life Sciences Limited is acquiring a 76% stake in IQGenX Pharma Private Limited for ₹9.12 crore. This acquisition expands Alivus's capabilities beyond active pharmaceutical ingredients into advanced formulation development. It aims to strengthen its integrated offering for pharmaceutical customers globally and broaden its CDMO services.